recent advances in treatment of age related macular degeneration
نویسندگان
چکیده
age related macular degeneration (amd) is the most common cause of visual impairment in the population above 64 years of age in developed countries. most cases of severe vision loss due to amd are caused by exudative changes in the macula. extensive research on amd has led to advances in its prophylaxis and treatment in recent years. photodynamic therapy (pdt) was developed in late 1990's in which free oxygen radicals damage the neovascular tissue in a non-thermal way. the first prophylactic treatment for amd was approved in 2001 which includes oral administration of a combination of vitamins, antioxidants, and minerals. it was shown that this treatment decreases the chance of progression of dry type amd to more advanced atrophy and choroidal neovascularization. laser treatment for drusen is currently under investigation. vitrectomy for removal of subretinal choroidal neovascularization (cnv) has proven not to be effective for visual improvement. translocation of fovea to an area away from cnv has met some success but the chance of loss of peripheral vision has hampered its general acceptance. an important area of research is the pharmacologic approach to counteract choroidal neovascularization. three groups of anti-angiogenic agents have been studied; 1) anti-vegf (vascular endothelial growth factor), 2) recombinant anti-vegf antibodies, and 3) steroids. transpupillary thermotherapy has been used for several years and was claimed to be effective for treatment of cnv in some small uncontrolled studies but failed to be more effective than sham treatment in a recent multicenter controlled trial. in general, it seems that the most promising areas of research in the treatment of amd are prophylactic treatment and antiangiogenic therapy.
منابع مشابه
Recent developments in the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is a common cause of visual loss in the elderly, with increasing prevalence due to increasing life expectancy. While the introduction of anti-VEGF therapy has improved outcomes, there are still major unmet needs and gaps in the understanding of underlying biological processes. These include early, intermediate, and atrophic disease stages. Recent studies h...
متن کاملthe genetics of age-related macular degeneration
age-related macular degeneration (amd) is the leading cause of blindness in old subjects. it is a multifactorial disease with both environmental and genetic factors playing some role in its pathogenesis. similar to many other genetic diseases, the inheritance pattern of amd does not fit into simple mendelian rules. these diseases are caused by the presence of multiple genetic factors and are ca...
متن کاملTreatment of dry age-related macular degeneration.
A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulatio...
متن کاملTreatment of Neovascular Age Related Macular Degeneration
Until the end of the last century, no intervention could alter the natural history of the disease. Only in the last few decades, the retina specialists began to intervene in order to minimize the visual loss in those patients. Last ten years have been especially exciting as the new treatment modalities emerged and for the first time we could not only halt the progression of the deterioration, b...
متن کاملTreatment of age-related macular degeneration
Age-related macular degeneration (AMD) is the greatest cause of legal blindness in the western world. Established treatments include argon laser photocoagulation of extrafoveal choroidal neovascularisation (CNV) and photodynamic therapy of selected sub-foveal CNV. Newer approaches are targeting the angiogenic pathway in CNV development. Currently, other treatment modalities, such as radiotherap...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
بیناجلد ۱۱، شماره ۱، صفحات ۱۱۶-۱۲۱
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023